Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported topline results from the phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the
Item 7.01. Regulation FD Disclosure. On June 7, 2022, Seres Therapeutics, Inc. posted a slide presentation on the topline data from the ECOSPOR IV open-label study of SER-109 in... | June 7, 2022
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated
THOUSAND OAKS (dpa-AFX) - Amgen, Inc. (AMGN) announced Tuesday positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients
Item 7.01. Regulation FD. On May 24, 2022, Motus GI Holdings, Inc. issued a press release announcing positive topline data from the European Union Feasibility Study of the Pure- Vu®... | May 24, 2022